Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component

PHASE2CompletedINTERVENTIONAL
Enrollment

338

Participants

Timeline

Start Date

July 1, 2014

Primary Completion Date

July 1, 2015

Study Completion Date

July 18, 2015

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

FF

Fluticasone furoate is available as fluticasone furoate inhalation powder (100 mcg per blister), combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)

DRUG

UMEC

Umeclidinium bromide is available as combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister)

DRUG

VI

Vilanterol is available as vilanterol inhalation powder (25 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)

Trial Locations (67)

3680

GSK Investigational Site, Kyiv

4000

GSK Investigational Site, San Miguel de Tucumán

GSK Investigational Site, San Miguel de Tucumán

5500

GSK Investigational Site, Mendoza

5600

GSK Investigational Site, San Rafael

10117

GSK Investigational Site, Berlin

10119

GSK Investigational Site, Berlin

20253

GSK Investigational Site, Hamburg

26505

GSK Investigational Site, Morgantown

28207

GSK Investigational Site, Charlotte

29303

GSK Investigational Site, Spartanburg

29340

GSK Investigational Site, Gaffney

29379

GSK Investigational Site, Union

29615

GSK Investigational Site, Greenville

29732

GSK Investigational Site, Rock Hill

30173

GSK Investigational Site, Hanover

45231

GSK Investigational Site, Cincinnati

49006

GSK Investigational Site, Dnipropetrovsk

49051

GSK Investigational Site, Dnipropetrovsk

55407

GSK Investigational Site, Minneapolis

60389

GSK Investigational Site, Frankfurt am Main

60596

GSK Investigational Site, Frankfurt am Main

61002

GSK Investigational Site, Kharkiv

61124

GSK Investigational Site, Kharkiv

63263

GSK Investigational Site, Neu-Isenburg

70584

GSK Investigational Site, Sunset

91786

GSK Investigational Site, Upland

92117

GSK Investigational Site, San Diego

92663

GSK Investigational Site, Newport Beach

97504

GSK Investigational Site, Medford

100184

GSK Investigational Site, Ploieşti

100379

GSK Investigational Site, Ploieşti

105229

GSK Investigational Site, Moscow

110084

GSK Investigational Site, Piteşti

115446

GSK Investigational Site, Moscow

194354

GSK Investigational Site, Saint Petersburg

194356

GSK Investigational Site, Saint Petersburg

197706

GSK Investigational Site, Sestroretsk

198216

GSK Investigational Site, Saint Petersburg

300310

GSK Investigational Site, Timișoara

400371

GSK Investigational Site, Cluj-Napoca

410012

GSK Investigational Site, Saratov

600252

GSK Investigational Site, Bacau

603126

GSK Investigational Site, Nizhny Novgorod

617507

GSK Investigational Site, Comuna Alexandru Cel Bun

675000

GSK Investigational Site, Blagoveshchensk

C1028AAP

GSK Investigational Site, Ciudad Autonoma de Buenos Aires

S2000DBS

GSK Investigational Site, Rosario

C1426ABP

GSK Investigational Site, Buenos Aires

T4000IFL

GSK Investigational Site, San Miguel de Tucumán

04109

GSK Investigational Site, Leipzg

06682

GSK Investigational Site, Teuchern

15-044

GSK Investigational Site, Bialystok

15-430

GSK Investigational Site, Bialystok

40-645

GSK Investigational Site, Katowice

25-734

GSK Investigational Site, Kielce

90-242

GSK Investigational Site, Lodz

60-214

GSK Investigational Site, Poznan

81-741

GSK Investigational Site, Sopot

95-100

GSK Investigational Site, Zgierz

88-400

GSK Investigational Site, Żnin

020125

GSK Investigational Site, Bucharest

050159

GSK Investigational Site, Bucharest

Unknown

GSK Investigational Site, Craiova

03680

GSK Investigational Site, Kiev

02091

GSK Investigational Site, Kyiv

02232

GSK Investigational Site, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02164539 - Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component | Biotech Hunter | Biotech Hunter